1. Considered and approved Audited Financial Results for the Quarter and Financial Year ended 31st March, 2025 along with the along with the Auditors Report thereon, Statement of Assets ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Choksi Laboratories' board approved audited results for FY25, with revenue from operations rising to ₹4,178.23 lakhs from ₹3,669.51 lakhs, a growth of about 13.9%. Net profit climbed to ₹152.33 lakhs from ₹110.98 lakhs, up roughly 37%, driven by higher sales and an 11.8% reduction in finance costs. EPS improved to ₹2.19 from ₹1.59. Operating cash flow remained healthy at ₹1,177.80 lakhs, though total borrowings stood at about ₹2,807 lakhs against equity of ₹2,360 lakhs. The auditor issued an unqualified opinion but flagged an Emphasis of Matter about a ransomware attack on May 22, 2025 that disrupted operations and delayed the original board meeting; recovery costs will be booked in the next financial year.
The results show solid profit growth and stable operations despite the cyber incident. Shareholders should watch for any further updates on the ransomware impact and related recovery costs, which could affect next year's expenses, while the strengthened earnings and positive cash flow are supportive for the stock.